Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus.

ABSTRACT:

Objective

To compare the efficacy and safety of the once-daily prandial glucagon-like peptide-1 receptor agonist lixisenatide with the dipeptidyl peptidase-4 inhibitor sitagliptin in patients aged <50 years affected by obesity and type 2 diabetes mellitus (T2DM).

Materials and methods

This was a 24-week, double-blind, randomized, parallel-group study. Obese patients with T2DM inadequately controlled on metformin were randomized to lixisenatide 20 μg once-daily injection (n = 158) or once-daily oral sitagliptin 100 mg (n = 161). The primary endpoint was the proportion of patients with a glycated hemoglobin (HbA_1c) <7% and ≥5% weight loss at 24 weeks.

Results

The proportion of patients that achieved the primary endpoint was 12.0% for lixisenatid

SUBMITTER: Van Gaal L 

PROVIDER: S-EPMC5685032 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature